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Abstract: 
Preeclampsia is a multi-system disorder characterized by hypertension, edema and proteinuria 
affecting between 5-10% of pregnancies. A subset of cases progress to severe preeclampsia 
with exacerbated hypertension/proteinuria and evidence of nervous system, liver and/or kidney 
dysfunction, in addition to fetal growth restriction. Soluble fms-like tyrosine kinase-1 (sFlt) is 
minimally expressed in many tissues, including the placenta, and is a circulating antagonist to 
vascular endothelial growth factor. With progression of pregnancy, sFlt levels significantly rise, 
especially in women who develop preeclampsia. Diagnostic tests to predict preeclampsia in 
pregnant women are limited and current tests measure total sFlt in relationship to placental 
growth factor with varying sensitivity and specificity. We hypothesized that a pregnancy-specific 
splice variant of sFlt (sFlt1-14), almost exclusively expressed by the placenta, would serve as 
an improved serum biomarker for the development of preeclampsia.  Monoclonal antibodies 
(mAbs) were developed that specifically bind the two predominant isoforms of sFlt (sFlt1 and 
sFlt1-14) by hybridoma generation from wild type mice immunized with c-terminal peptides of 
the two isoforms. Western blot, ELISA and affinity analysis indicated the mAbs were specific for 
sFlt1 or sFlt1-14 splice variants and recognized these proteins in biological fluids (amniotic fluid 
or serum).  A quantitative capture ELISA was developed whereby total sFlt in biological fluid is 
captured by a unique human mAb and specific levels of sFlt1 or sFlt1-14 are detected by their 
respective mouse mAb, followed by anti-murine secondary antibody development. Using 
recombinant sFlt1 or sFlt1-14 as standards, these endogenous proteins were quantified in 
commercially available third trimester human pregnant sera. Future studies will measure these 
isoforms in sera prospectively collected from women with known outcomes of a healthy 
pregnancy or preeclampsia and the ability of absolute quantitation of the isoform(s) or a ratio of 
the two to predict the likely onset and severity of preeclampsia will be evaluated.   
